PT  - JOURNAL ARTICLE
AU  - Samuel Valenca
AU  - Thiago Ferreira
AU  - Alan Lopes
AU  - Denise Cardoso
AU  - Karla Pires
AU  - Larissa Silva-Neto
AU  - Manuella Lanzetti
AU  - Jackson Alves
AU  - Eduardo Trajano
AU  - Renata Nesi
AU  - Marina Barroso
AU  - Romulo Pinto
AU  - Cláudia Benjamim
AU  - Luís Porto
TI  - Differential effects of atorvastatin, pravastatin, rosuvastatin and simvastatin on lungs from mice exposed to cigarette smoke
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P3745
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P3745.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P3745.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Short-term cigarette smoke (CS) exposure leads to acute lung inflammation through its influence on oxidants/antioxidants imbalance, but lately statins have shows anti-inflammatory and antioxidant effects. Therefore, we aimed analyzing the effects of four different statins on the lungs of mice exposed CS. Male C57Bl/6 mice were divided into six groups (n=8 each): Mice exposed to the smoke from 12 cigarettes/day/5 days (CS group); exposed to smoke from 12 cigarettes per day for 5 days plus atorvastatin (10 mg/kg/day; CS+A group), or pravastatin (5 mg/kg/day; CS+P group), or rousovastatin (5 mg/kg/day; CS+R group) or sinvastatin (20 mg/kg/day; CS+S group); control group was sham-smoked. One day after the last CS exposure, mice were sacrificed, the bronchoalveolar lavage fluid (BAL) was performed and the lungs were removed for histological analysis and homogenized for biochemical analyses. Oxidant levels were reduced in CS+S (p<0.05); DPPH levels were increased in CS+A, CS+R and CS+S (p<0.05); nitrite levels were reduced in CS+P, CS+R and CS+S (p<0.05); MCP-1 levels were reduced in CS+R and CS+S (p<0.01); hydroperoxides levels were reduced in CS+A, CS+R and CS+S (p<0.001); catalase activity was reduced in CS+P (p<0.01); SOD activity were reduced in CS+A, CS+P (p<0.01) CS+R and CS+S (p<0.05) all when compared with CS group. These results suggest that simvastatin is the best treatment for acute lung injury induced by CS due to reduction of inflammatory and oxidant markers.